The University of Virginia is conducting a clinical research study for adults ages 18 and over, who have advanced solid tumors. The purpose of this study is to determine the maximum tolerated dose (or the highest dose that is safe and effective) of an investigational drug called KSQ-4279.
This study is evaluating the study drug, KSQ-4279 alone, and in combination with other therapies. The study treatment that you receive will depend on what part of the study is available when you enroll. There are three study treatment possibilities:
• KSQ-4279 alone
• KSQ-4279 in combination with olaparib
• KSQ-4279 in combination with carboplatin
KSQ-4279 is available as a capsule to be taken by mouth. If you are also receiving olaparib, you will also take it by mouth. If you are receiving carboplatin, you will receive this medication via infusion at the site. There is an unlimited amount of cycles of the investigational drug in this study as long as your disease remains stable and does not progress.
Study-related materials will be provided free of charge.
Additional information can be found here: https://clinicaltrials.gov/ct2/show/NCT05240898
Reimbursement of $0.54 per mile; Up to $175 per night for hotel